trans-Tranilast|cas 70806-55-2|DC Chemicals

Cas No.:	70806-55-2
Chemical Name:	Tranilast
Synonyms:	trans-Tranilast;2-{[(2E)-3-(3,4-Dimethoxyphenyl)-2-propenoyl]amino}benzoic acid;(3',4'-dimethoxycinnamoyl)-anthranilic acid;(3.4-Dimethoxy-benzal)-anthranilsaeure;(3.4-Dimethoxy-benzyliden)-anthranilsaeure;(E)-2-{[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino}benzoic acid;2-(3,4-dimethoxycinnamoylamino)benzoic acid;2-(3.4-Dimethoxy-benzalamino)-benzoesae;AC1L86AG;N-(3,4-dimethoxybenzylidene)anthranilic acid;NSC405414;N-veratryliden-anthranilic acid;tranilast (N-(3',4'-dimethoxycinnamoyl)anthranilic acid);N-5';N-5';AB00382987-19;AB00382987-19;NCGC00261878-01;NCGC00261878-01;53902-17-3;53902-17-3;SMR000058373;SMR000058373;NCGC00021458-04;NCGC00021458-04;HMS3648A16;HMS3648A16;AB00382987_21;AB00382987_21;NC00171;NC00171;MK 341;SB 252218;MK 341;SB 252218;N-(3 ,4 -dimethoxycinnamoyl)anthranilic acid;N-(3 ,4 -dimethoxycinnamoyl)anthranilic acid;N-(3,4-Dimethoxycinnamoyl)anthranilic acid;N-(3,4-Dimethoxycinnamoyl)anthranilic acid;2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid;2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid;SDCCGSBI-0051160.P004;SDCCGSBI-0051160.P004;NCGC00018185-06;NCGC00018185-06;DTXCID403693;DTXCID403693;NSC 758970;NSC 758970;Tranilast (trans-);Tranilast (trans-);Q27164069;Q27164069;BD164491;BD164491;HMS2094I21;HMS2094I21;AB00382987-18;AB00382987-18;2-{[(2e)-3-(3,4-Dimethoxyphenyl)prop-2-Enoyl]amino}benzoic Acid;2-{[(2e)-3-(3,4-Dimethoxyphenyl)prop-2-Enoyl]amino}benzoic Acid;HSCI1_000076;SR-01000003092-2;HSCI1_000076;MLS006010043;SR-01000003092-2;MLS001065902;MLS006010043;AMY14167;MLS001065902;Rizaben;AMY14167;Rizaben;D27;D27;Tranilastum [INN-Latin];Tranilastum [INN-Latin];n-(3',4'-dimethoxycinnamoyl) anthranilic acid;n-(3',4'-dimethoxycinnamoyl) anthranilic acid;AC-940;Q2325594;AC-940;53902-12-8;Q2325594;GTPL6326;53902-12-8;BCP06359;GTPL6326;KS-1193;BCP06359;s5871;KS-1193;BDBM21613;s5871;Rizaben (TN);BDBM21613;NCGC00018185-10;Rizaben (TN);HMS3713J04;NCGC00018185-10;2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid;HMS3713J04;AC-35254;2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid;HMS3263P07;AC-35254;Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-;HMS3263P07;HMS3412G17;Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-;Tranilastum;HMS3412G17;SB 252218;Tranilastum;2-[3-(3,4-dimethoxyphenyl)prop-2-enoylamino]benzoic acid;SB 252218;SPECTRUM1505333;2-[3-(3,4-dimethoxyphenyl)prop-2-enoylamino]benzoic acid;HMS2230F18;SPECTRUM1505333;NCGC00018185-08;SCHEMBL29875;HMS2230F18;2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propen-1-yl]amino]benzoic Acid;NCGC00018185-08;tranilast;SCHEMBL29875;TRANILAST [INN];2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propen-1-yl]amino]benzoic Acid;BSPBio_003561;tranilast;MK 341;TRANILAST [INN];AKOS002841076;BSPBio_003561;NCGC00018185-23;MK 341;HVF50SMY6E;AKOS002841076;TRANILAST [MART.];NCGC00018185-23;HB...
SMILES:	O=C(O)C1=CC=CC=C1NC(/C=C/C2=CC(OC)=C(OC)C=C2)=O
Formula:	C₁₈H₁₇NO₅
M.Wt:	327.34
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

trans-Tranilast For the detailed information of trans-Tranilast, the solubility of trans-Tranilast in water, the solubility of trans-Tranilast in DMSO, the solubility of trans-Tranilast in PBS buffer, the animal experiment (test) of trans-Tranilast, the cell expriment (test) of trans-Tranilast, the in vivo, in vitro and clinical trial test of trans-Tranilast, the EC50, IC50,and affinity,of trans-Tranilast, For the detailed information of trans-Tranilast, the solubility of trans-Tranilast in water, the solubility of trans-Tranilast in DMSO, the solubility of trans-Tranilast in PBS buffer, the animal experiment (test) of trans-Tranilast, the cell expriment (test) of trans-Tranilast, the in vivo, in vitro and clinical trial test of trans-Tranilast, the EC50, IC50,and affinity,of trans-Tranilast, Please contact DC Chemicals.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.